Mi­rati and MD An­der­son team up on KRAS; Sanofi inks deal with a Har­vard spin­out for oral bi­o­log­ics

Mi­rati, the oth­er KRAS-fo­cused biotech, is get­ting some ex­tra am­mo as it looks to leapfrog Am­gen in the hunt for the first, most ef­fec­tive and most broad­ly ef­fec­tive for one of the most ubiq­ui­tous and hard-to-hit onco­genes.

The Cal­i­for­nia biotech has signed a re­search and de­vel­op­men­tal with MD An­der­son to help ad­vance both Mi­rati’s lead KRAS G12C mol­e­cule — the one that’s now proven ef­fec­tive in cer­tain lung can­cer pa­tients — and a pre­clin­i­cal mol­e­cule that goes af­ter an­oth­er KRAS mu­ta­tion, G12D. The Texas-based re­search in­sti­tute will help Mi­rati de­sign and run pre­clin­i­cal and clin­i­cal stud­ies for sev­er­al sol­id tu­mors, in­clud­ing non-small cell lung, pan­cre­at­ic, col­orec­tal and gy­ne­co­log­i­cal can­cers, over the next 5 years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.